Patents by Inventor Richard Kolesnick

Richard Kolesnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080096840
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gfRas mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Application
    Filed: October 12, 2007
    Publication date: April 24, 2008
    Inventors: Richard Kolesnick, Hongmei Xing
  • Publication number: 20070157331
    Abstract: Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.
    Type: Application
    Filed: March 7, 2007
    Publication date: July 5, 2007
    Applicant: Massachusetts General Hospital, Partners HealthCare Research Ventures & Licensing
    Inventors: Johnathan Tilly, Richard Kolesnick
  • Publication number: 20060252037
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided.
    Type: Application
    Filed: May 29, 2003
    Publication date: November 9, 2006
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Richard Kolesnick, Hingmei Xing
  • Publication number: 20050037455
    Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions aree provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gƒ Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
    Type: Application
    Filed: December 3, 2003
    Publication date: February 17, 2005
    Inventors: Richard Kolesnick, Hongmei Xing
  • Patent number: 6790627
    Abstract: The present invention relates, first, to methods for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis. The present invention further relates to methods for the identification of compounds which modulate (i.e., either increase or decrease) sensitivity to ASM-related processes, including apoptosis.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 14, 2004
    Assignees: Sloan-Kettering Institute for Cancer Research, Mount Sinai School of Medicine of New York University
    Inventors: Richard Kolesnick, Edward H. Schuchman
  • Publication number: 20010055774
    Abstract: The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis. The present invention further relates to methods for the identification of compounds which modulate (i.e., either increase or decrease) sensitivity to ASM-related processes, including apoptosis.
    Type: Application
    Filed: August 13, 2001
    Publication date: December 27, 2001
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard Kolesnick, Edward H. Schuchman
  • Patent number: 6274309
    Abstract: The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis. The present invention further relates to methods for the identification of compounds which modulate (i.e., either increase or decrease) sensitivity to ASM-related processes, including apoptosis.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: August 14, 2001
    Inventors: Richard Kolesnick, Edward H. Schuchman